PlaqueTec raised $5 million in an oversubscribed financing round led entirely by existing investors, funding continued work on its BIOPATTERN clinical trial for coronary artery disease biomarkers. The company is using an intracoronary sampling approach to collect blood proteins directly at sites of plaque formation, aiming to generate data not obtainable from conventional peripheral blood draws. PlaqueTec said proteomic and clinical data from the trial will populate a database called BioCarta to support drug target selection and patient stratification efforts, while the company begins discussions with potential biopharma partners. The financing indicates sponsor interest in biomarker platforms that aim to sharpen translational linkage between local plaque biology and systemic measurement strategies.